Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Correction to: Nature Medicine https://doi.org/10.1038/s41591-019-0628-7. Published online 4 November 2019.

In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.